Last reviewed · How we verify
PF-06882961 Immediate Release Tablet
At a glance
| Generic name | PF-06882961 Immediate Release Tablet |
|---|---|
| Sponsor | Pfizer |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Study to Learn How Different Forms of The Study Medicine Called Danuglipron Are Taken up Into the Blood In Healthy Adults (PHASE1)
- STUDY TO COMPARE PHARMACOKINETICS (PK) OF SINGLE ORAL DOSES OF DIFFERENT PF-06882961 FORMULATIONS IN PARTICIPANTS WHO ARE OVERWEIGHT OR HAVE OBESITY (PHASE1)
- A Single Dose Crossover Study In Healthy Subjects To Evaluate Different Formulations Of PF-06882961 (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PF-06882961 Immediate Release Tablet CI brief — competitive landscape report
- PF-06882961 Immediate Release Tablet updates RSS · CI watch RSS
- Pfizer portfolio CI